Dr. Mills seems to have revived his high confidence level in Prochymal and did an excellent job in today's conference call. I got the impression that Prochymal did much better in the Phase III tests than everyone had initially thought. He obviously didn't want to reveal any intellectual property secrets, therefore he gave only enough information to assure investors that better times are ahead.

It was great to hear that the EAP program is picking up the pace and some new patients are coming into the program from the same doctors. Prochymal is beginning to be recognized by some doctors as the best GvHD treatment. Repeat businness breeds word-of-mouth new business, as doctors will tell other doctors. Success rate was quoted as being 60% in the EAP program.

I'm convinced that Prochymal will be FDA approved for GvHD, for at least Liver and GI and perhapse even for Stage D Skin.

If you haven't listened to the conference call, I suggest you do so now.